Edgewise Therapeutics, Inc.
EWTX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.46 | -5.39 | -0.93 | -3.12 |
| FCF Yield | -2.37% | -1.81% | -1.10% | -1.11% |
| EV / EBITDA | -31.37 | -44.55 | -62.27 | -61.85 |
| Quality | ||||
| ROIC | -7.18% | -10.58% | -9.82% | -8.20% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.86 | 0.90 | 0.93 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 13.92% | -39.22% | 2.38% | -5.98% |
| Safety | ||||
| Net Debt / EBITDA | 0.92 | 0.99 | 0.95 | 1.01 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,320.63 | -1,427.82 | -474.14 | -222.01 |